PSMD7抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P00654(PSMD7 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P00654(PSMD7 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The PSMD7 antibody is a research tool designed to detect and study the Proteasome 26S Subunit, Non-ATPase 7 (PSMD7), a key component of the 26S proteasome. The 26S proteasome is a large multiprotein complex responsible for degrading ubiquitinated proteins, playing a critical role in maintaining cellular protein homeostasis, regulating cell cycle progression, and modulating stress responses. PSMD7. also known as Rpn8. is part of the 19S regulatory particle (RP) that recognizes and deubiquitinates substrates before their translocation into the 20S catalytic core for proteolysis.

Antibodies targeting PSMD7 are widely used in molecular biology and disease research to investigate proteasome structure, function, and dysregulation in conditions like cancer, neurodegenerative disorders, and autoimmune diseases. They enable techniques such as Western blotting, immunohistochemistry, and immunoprecipitation to assess PSMD7 expression levels, localization, and interactions within the proteasome complex.

Commercial PSMD7 antibodies are typically developed in hosts like rabbits or mice, validated for specificity through knockout controls or siRNA knockdown. Researchers utilize these antibodies to explore mechanisms of proteasome inhibitors in cancer therapy or to study proteostasis imbalances in Alzheimer’s or Parkinson’s disease. However, variability in antibody performance across experimental conditions necessitates careful validation for each application. Overall, PSMD7 antibodies serve as essential tools for dissecting proteasome biology and its implications in health and disease.